Homann J - Search Results

1

New aspects of liver abnormalities as part of the systemic mast cell activation syndrome.

Alfter K, von Kügelgen I, Haenisch B, Frieling T, Hülsdonk A, Haars U, Rolfs A, Noe G, Kolck UW, Homann J, Molderings GJ. Alfter K, et al. Among authors: homann j. Liver Int. 2009 Feb;29(2):181-6. doi: 10.1111/j.1478-3231.2008.01839.x. Epub 2008 Jul 23. Liver Int. 2009. PMID: 18662284

2

Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder.

Molderings GJ, Kolck UW, Scheurlen C, Brüss M, Homann J, Von Kügelgen I. Molderings GJ, et al. Among authors: homann j. Scand J Gastroenterol. 2007 Sep;42(9):1045-53. doi: 10.1080/00365520701245744. Scand J Gastroenterol. 2007. PMID: 17710669

3

[Systemic mastocytosis--definition of an internal disease].

Homann J, Kolck UW, Ehnes A, Frieling T, Raithel M, Molderings GJ. Homann J, et al. Med Klin (Munich). 2010 Aug;105(8):544-53. doi: 10.1007/s00063-010-1093-8. Epub 2010 Sep 8. Med Klin (Munich). 2010. PMID: 20824412 Review. German.

4

Comparative analysis of mutation of tyrosine kinase kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects.

Molderings GJ, Meis K, Kolck UW, Homann J, Frieling T. Molderings GJ, et al. Among authors: homann j. Immunogenetics. 2010 Dec;62(11-12):721-7. doi: 10.1007/s00251-010-0474-8. Epub 2010 Sep 14. Immunogenetics. 2010. PMID: 20838788

5

Ureteral stones due to systemic mastocytosis: diagnostic and therapeutic characteristics.

Molderings GJ, Solleder G, Kolck UW, Homann J, Schröder D, von Kügelgen I, Vorreuther R. Molderings GJ, et al. Among authors: homann j. Urol Res. 2009 Aug;37(4):227-9. doi: 10.1007/s00240-009-0198-0. Epub 2009 Jun 10. Urol Res. 2009. PMID: 19513706

6

Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options.

Molderings GJ, Brettner S, Homann J, Afrin LB. Molderings GJ, et al. Among authors: homann j. J Hematol Oncol. 2011 Mar 22;4:10. doi: 10.1186/1756-8722-4-10. J Hematol Oncol. 2011. PMID: 21418662 Free PMC article. Review.

7

Omalizumab treatment of systemic mast cell activation disease: experiences from four cases.

Molderings GJ, Raithel M, Kratz F, Azemar M, Haenisch B, Harzer S, Homann J. Molderings GJ, et al. Among authors: homann j. Intern Med. 2011;50(6):611-5. doi: 10.2169/internalmedicine.50.4640. Epub 2011 Mar 15. Intern Med. 2011. PMID: 21422688 Free article.

8

Determination of plasma heparin level improves identification of systemic mast cell activation disease.

Vysniauskaite M, Hertfelder HJ, Oldenburg J, Dreßen P, Brettner S, Homann J, Molderings GJ. Vysniauskaite M, et al. Among authors: homann j. PLoS One. 2015 Apr 24;10(4):e0124912. doi: 10.1371/journal.pone.0124912. eCollection 2015. PLoS One. 2015. PMID: 25909362 Free PMC article.

9

Pharmacological treatment options for mast cell activation disease.

Molderings GJ, Haenisch B, Brettner S, Homann J, Menzen M, Dumoulin FL, Panse J, Butterfield J, Afrin LB. Molderings GJ, et al. Among authors: homann j. Naunyn Schmiedebergs Arch Pharmacol. 2016 Jul;389(7):671-94. doi: 10.1007/s00210-016-1247-1. Epub 2016 Apr 30. Naunyn Schmiedebergs Arch Pharmacol. 2016. PMID: 27132234 Free PMC article. Review.

10

Lower prevalence of vitamin D insufficiency in German patients with systemic mast cell activation syndrome compared with the general population.

Wirz S, Hertfelder HJ, Seidel H, Homann J, Molderings GJ. Wirz S, et al. Among authors: homann j. Z Gastroenterol. 2017 Dec;55(12):1297-1306. doi: 10.1055/s-0043-121346. Epub 2017 Dec 6. Z Gastroenterol. 2017. PMID: 29212100 English.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

88 results

Search Page

Filters